Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


J&J, Hacker Work Together To Fix Insulin Pump Vulnerability

Executive Summary

US FDA says the collaborative approach taken by an independent security researcher and Johnson & Johnson/Animas in responding to a potentially fatal cybersecurity vulnerability with the firm's Animas OneTouch Ping insulin pump should be a model for the industry that aligns with the agency's recent draft guidance.

You may also be interested in...

Lack Of Funding Stalls Major US FDA Cybersecurity Initiative

A public-private partnership board long touted by top US FDA officials to help address cybersecurity threats has hit a funding wall. The agency received less than half of what it asked for in the FY 2019 budget for its digital efforts, including its cybersecurity strategy, leading it to make some tough choices.

US Homeland Security Sees Rapid Growth In Device Cybersecurity Vulnerability Reports

A center inside the US Department of Homeland Security has seen a massive spike in the number of potential medical device cybersecurity vulnerabilities that it has responded to in the past year. The government says it reflects better collaboration and disclosure policies in industry.

Digital Health, Cybersecurity Would See Significant Chunk Of FDA Device-Funding Boost

If Congress approves a 26% higher 2019 funding request for US FDA's device center, a substantial chunk of those dollars would go to building a novel framework for regulating digital-health technologies, and to help FDA and device manufacturers respond better to cybersecurity vulnerabilities, among other program priorities, according to agency officials.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts